V. L. Serebruany

466 total citations
10 papers, 361 citations indexed

About

V. L. Serebruany is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, V. L. Serebruany has authored 10 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 4 papers in Internal Medicine and 3 papers in Surgery. Recurrent topics in V. L. Serebruany's work include Antiplatelet Therapy and Cardiovascular Diseases (7 papers), Atrial Fibrillation Management and Outcomes (5 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). V. L. Serebruany is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (7 papers), Atrial Fibrillation Management and Outcomes (5 papers) and Venous Thromboembolism Diagnosis and Management (4 papers). V. L. Serebruany collaborates with scholars based in United States, Norway and Denmark. V. L. Serebruany's co-authors include Alex Pokov, Mohamed H. Kotob, Dan Atar, Justin Stebbing, Alexander H. Glassman, Dan Atar, J J Ferguson, Benjamin Oshrine, David C. Sane and Cathal O’Connor and has published in prestigious journals such as European Heart Journal, Journal of Thrombosis and Haemostasis and European Journal of Heart Failure.

In The Last Decade

V. L. Serebruany

10 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. L. Serebruany United States 8 321 122 105 40 40 10 361
Alex Pokov United States 11 496 1.5× 241 2.0× 153 1.5× 68 1.7× 85 2.1× 16 595
Julie K. Brooks United States 4 234 0.7× 89 0.7× 47 0.4× 47 1.2× 63 1.6× 6 326
Luciana Mucci Italy 7 244 0.8× 86 0.7× 82 0.8× 138 3.5× 81 2.0× 8 385
Michelle Dooley Ireland 5 324 1.0× 89 0.7× 107 1.0× 186 4.7× 31 0.8× 6 402
Joseph Carvajal France 4 420 1.3× 229 1.9× 152 1.4× 32 0.8× 46 1.1× 8 474
Murali Kodali United States 8 265 0.8× 99 0.8× 89 0.8× 83 2.1× 59 1.5× 12 310
Takamichi Ono Japan 8 249 0.8× 112 0.9× 34 0.3× 40 1.0× 51 1.3× 11 308
Sarah Endemann United States 4 479 1.5× 280 2.3× 157 1.5× 50 1.3× 76 1.9× 5 562
Megha Kureti United States 8 328 1.0× 165 1.4× 94 0.9× 18 0.5× 36 0.9× 12 361
Jurrien M. ten Berg Netherlands 6 262 0.8× 124 1.0× 54 0.5× 23 0.6× 43 1.1× 8 276

Countries citing papers authored by V. L. Serebruany

Since Specialization
Citations

This map shows the geographic impact of V. L. Serebruany's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. L. Serebruany with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. L. Serebruany more than expected).

Fields of papers citing papers by V. L. Serebruany

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. L. Serebruany. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. L. Serebruany. The network helps show where V. L. Serebruany may publish in the future.

Co-authorship network of co-authors of V. L. Serebruany

This figure shows the co-authorship network connecting the top 25 collaborators of V. L. Serebruany. A scholar is included among the top collaborators of V. L. Serebruany based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. L. Serebruany. V. L. Serebruany is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
2.
3.
Serebruany, V. L., Justin Stebbing, & Dan Atar. (2007). Dyspnoea after antiplatelet agents: the AZD6140 controversy. International Journal of Clinical Practice. 61(3). 529–533. 24 indexed citations
4.
Pokov, Alex, et al.. (2006). Validation of a VerifyNow-P2Y12 cartridge for monitoring plateletinhibition with clopidogrel. Methods and Findings in Experimental and Clinical Pharmacology. 28(5). 315–315. 120 indexed citations
5.
Serebruany, V. L., et al.. (2006). Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. International Journal of Clinical Practice. 60(8). 993–1002. 21 indexed citations
6.
Serebruany, V. L.. (2006). Platelet function analyzer (PFA‐100)TM closure time in the evaluation of platelet disorders and platelet function: a rebuttal. Journal of Thrombosis and Haemostasis. 4(6). 1428–1429. 4 indexed citations
7.
Serebruany, V. L., et al.. (2006). Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgraduate Medical Journal. 82(968). 404–410. 32 indexed citations
8.
Serebruany, V. L., Alexander H. Glassman, Dan Atar, et al.. (2003). Selective Serotonin Reuptake Inhibitors Yield Additional Antiplatelet Protection in Patients with Congestive Heart Failure Treated with Antecedent Aspirin. European Journal of Heart Failure. 5(4). 517–521. 65 indexed citations
9.
Serebruany, V. L., Marcus E. McKenzie, Paul A. Gurbel, et al.. (2002). Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure (EPCOT Trial). European Journal of Heart Failure. 4(4). 461–467. 30 indexed citations
10.
Atar, Dan, et al.. (1993). Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine.. PubMed. 6(4). 349–53. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex Pokov Breakdown of academic impact, for papers by Julie K. Brooks Breakdown of academic impact, for papers by Luciana Mucci Breakdown of academic impact, for papers by Michelle Dooley Breakdown of academic impact, for papers by Joseph Carvajal Breakdown of academic impact, for papers by Murali Kodali Breakdown of academic impact, for papers by Takamichi Ono Breakdown of academic impact, for papers by Sarah Endemann Breakdown of academic impact, for papers by Megha Kureti Breakdown of academic impact, for papers by Jurrien M. ten Berg
Rankless by CCL
2026